Author

D. S. Ziegler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

C. Mayoh· 2 shared F. Alvaro· 2 shared L. M. Lau· 2 shared M. Haber· 2 shared M. Wong· 2 shared O. Vittorio· 2 shared V. Tyrrell· 2 shared W. Nicholls· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Mayoh

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas

A. M. Fordham, L. M. Brown, C. Mayoh, A. Salib, Z. A. Barger, M. Wong, T. C. C. L. K. Sian, J. Xie, K. Gunther, P. Trebilcock, R. L. Terry, P. Barahona, P. Ajuyah, A. Sherstyuk, A. Avila, , E. D. Fleuren

The paper identifies FGFR aberrations as actionable targets in pediatric and AYA sarcomas using multi-platform profiling and shows FGFR inhibitors can inhibit tumor growth in PDX models.

bioRxiv · Jul 19, 2023 · PreprintCancer Biology

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

R. J. Duchatel, E. R. Jackson, S. G. Parackal, C. Sun, P. Daniel, A. Mannan, I. J. Findlay, D. Staudt, Z. P. Germon, S. Laternser, D. Kiltschewskij, P. S. Kearney, M. F. B. Jamaluddin, A. M. Douglas, T. Beitaki, , M. D. Dun

This study identifies PI3K/mTOR as a targetable genetic dependency in DIPG and demonstrates that combining paxalisib with metformin improves survival in xenograft models.

bioRxiv · Apr 17, 2023Cancer Biology

A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

C. Mayoh, A. Gifford, R. Terry, L. M. Lau, M. Wong, P. Rao, T. Shai-Hee, F. Saletta, D.-A. Khuong-Quang, V. Qin, M. Mateos, D. Meyran, K. E. Miller, A. Yuksel, E. V. Mould, , P. G Ekert

The paper develops a 15-gene immune signature to identify T-cell infiltration in high-risk paediatric cancers, finding up to 31% of such cancers have infiltrating T-cells.

bioRxiv · Sep 16, 2022 · PreprintCancer Biology

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T. Gargett, L. M. Ebert, N. T. H. Truong, P. M. Kollis, K. Sedivakova, W. Yu, E. C. F. Yeo, N. L. Wittwer, B. L. Gliddon, M. N. Tea, R. Ormsby, J. Nowicki, S. Poonnoose, O. Vittorio, D. S. Ziegler, , M. P. Brown

This study demonstrates that GD2-targeting CAR-T cells, enhanced with IL-15 transgene expression, effectively control glioblastoma growth in a preclinical model and are clinically feasible.

bioRxiv · May 1, 2022Immunology